The Role of Radiotherapy for Pancreatic Malignancies- A Population-based Analysis of the SEER-Medicare Database.

yunxiu luo (ruoshuiluo@gmail.com)
Hainan province cancer hospital https://orcid.org/0000-0002-0071-5482

Shengjun Xiao
Guilin Medical University 2nd Affiliated Hospital

Research

Keywords: pancreatic cancer, prognosis, surgery, radiotherapy

DOI: https://doi.org/10.21203/rs.3.rs-120622/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License.
Read Full License
Abstract

Background and objective. To investigate the role of adjuvant radiotherapy in patients after surgical resection for pancreatic cancer. Methods and patients. The patients with pancreatic cancer from 18 registered institutions in the Surveillance Epidemiology and End Results (SEER) database were retrospectively analyzed. The characteristics of patients who would benefit from adjuvant radiotherapy were screened, as well as whether neoadjuvant or adjuvant radiotherapy conferred to a better clinical outcome.

Results. 30249 patients included in this study (21295 vs 8954 in surgery and adjuvant radiotherapy group). The median survivals in the surgery (S) group and adjuvant radiotherapy (S+R) group were 24 and 21 months respectively. The 1, 3, and 5-year overall survival (OS) rates in the S group and S+R group were 68%, 40%, 31%, and 75%, 30%, 20%, respectively (p<0.001). Stratified analysis showed patients with histological classified as adenocarcinoma (15 VS 21, P<0.0001), infiltrating duct carcinoma (17 VS 21, P<0.0001), adenosquamous carcinoma (10 VS 18, P<0.0001) could be benefit from adjuvant radiotherapy. Adjuvant radiotherapy was helpful to improve the OS for patients with pancreatic head (19 VS 21, P=0.0003) and duct carcinoma (18VS 28, P=0.0121). Subgroup stratified assay indicated specific patients with early stage (AJCC 7th I, II, T2, N0) pancreatic carcinoma had better OS after additional radiotherapy than surgery alone.

Conclusion. Additional radiotherapy may contribute to improved prognosis for patients with pancreatic carcinoma of specific histological types (adenocarcinoma/carcinoma, infiltrating duct carcinoma, adenosquamous carcinoma, and squamous), anatomical location, and advanced stage. A specific subgroup of patients with an early stage (I/II, T2) pancreatic cancer should be considered for additional radiotherapy.

1 Introduction

Pancreatic cancer is the seventh leading cause of cancer-related mortality, with an estimated 458918 of new cases and 432242 of deaths worldwide in 2018. 1 It is predicted that pancreatic cancer will become the third cause of cancer-related death in the future. 2 Unfortunately, a multimodal therapy has not been able to improve pancreatic cancer patients’ prognosis. Surgery remains the most important treatment, but only 10–15% of patients are candidates for potentially curative resection, given that most patients would have atypical clinical symptoms and therefore present at the late advanced stage of the disease and not amenable for curative surgery. At present, the 5-year survival rate for pancreatic cancers is poor at less than 20%. Adjuvant radiotherapy and chemotherapy have been shown to improve the survival outcome of patients with pancreatic cancers, while neoadjuvant radiotherapy as well as intraoperative radiotherapy have also contributed to the improved prognosis. However, patient selection of suitability for additional radiotherapy or the optimal timing between the application of radiotherapy and surgery remains unclear.
To investigate the impact of adjuvant radiotherapy in patients after surgical resection for pancreatic cancer, we retrospectively analyzed patients from 18 registered institutions in the Surveillance Epidemiology and End Results (SEER) Medicare linked database. We aimed to determine the characteristics of patients that would benefit from adjuvant radiotherapy, and whether neoadjuvant or adjuvant radiotherapy conferred to a better clinical outcome.

2 Methods And Patients

2.1 Data sources

The SEER*Stat software (version8.3.5) was used to retrieve data from the SEER database containing the SEER 18 registries (November 2018 submission). These registries covered approximately 90% of the US population (based on 201 censuses) from 1973–2016.

2.2 Patients

SEER-Medicare patients diagnosed with pancreatic malignancies with site code C25.0-c25.9, and with the International Classification of Disease for Oncology, Third Edition, (ICD-O-3) histological classification codes of 8000 and 9260 were included in our study. Data on diagnosis confirmation, summary stage, American Joint Committee on Cancer (AJCC) 7th Editor all stage, T, N, M stage, histological grade, primary site surgery, regional lymph node surgery, the sequence of surgery and radiotherapy, radio source, chemotherapy, overall survival in months, and survival status were collected. Meanwhile, patient's basic demographics including age, pancreatic cancer diagnosis, and race were also gathered. Patients were excluded if data on survival or any survival status were not available.

Patients who underwent surgery were compared with patients who received surgery and radiotherapy. To identify the characteristics of patients that would benefit from adjuvant radiotherapy, the association of additional radiotherapy on survival with varying tumor histology, AJCC stage, age, race, primary site, grade, surgery primary site, regional lymph node surgery, and chemotherapy were analyzed. Covariates of interest included patient-related factors (age, gender, race), disease-level factors (primary site, stage, grade, histologic classification), treatment-related factors (surgery methods, radiotherapy, the sequence between surgery and radiotherapy, chemotherapy, diagnosis confirmation).

2.3 Statistics

The Fisher Exact Probability and ANOVA test were used to compare differences between categorical variables and continuous variables, respectively. The Cox proportional hazards regression model was used to determine the effects of variables on OS and to visualize the survival curves, which were adjusted for other significant prognostic factors. All calculations were performed with SPSS version 23.0 for Windows software (IBM Corporation, Chicago, IL) and EmpowerStat software, GraphPad prism 7.0.

3 Results
A total of 243,417 patients with pancreatic malignancy were identified from the SEER-Medicare data for the years of 1975–2016. Of these, 7,864 patients did not have survival data, and 43,722 patients whose survival time was 0 month, thus excluded from our analysis. A total of 115,371 patients did not undergo surgery, and in 46,211 patients, surgical data were not available, thus these were also eliminated. Lastly, 30,249 patients met the inclusion criteria and were included in our study. The selection of patients was shown in Figure s1.

3.1 Baseline characteristics of patients.

Of the 30,249 patients included in this study, 21,295 were in the surgery group (S group), and 8,954 were in the combined surgery and radiotherapy group (S + R group). The demographics of the two groups were shown in Table S1.

Patients in the S group were significantly older and more likely to be female than the S + R group. There were more tumors located at pancreatic body and tail in the S group whereas a higher number of pancreatic head tumors were found in the S + R group. Most histological types of adenocarcinoma, carcinoma, and infiltrating duct carcinoma were identified in the S + R group, while there were more neuroendocrine neoplasms recorded in the S group. Patients with local-stage (AJCC 7th stage I, T0-2, N0, M0) disease underwent local excision (including lymph node biopsy) in the S group and patients in the S + R group were mostly with regional-stage (AJCC 7th stage II, T 3–4, N1) and received regional surgery as well as chemotherapy. There were no significant differences in follow time and histologic grade between the 2 groups. More patients were still alive in the S group at the last follow-up.

3.2 Analysis of survival and risk factor

The overall median survival of all patients was 23 months, with the 1, 3, 5-year survival rate of 49%, 32%, and 25% respectively. The median survivals in the S and S + R group were 24 and 21 months respectively, as demonstrated in Fig. 1a. The 1, 2, 3, and 5-year overall survival (OS) rates in the S group were 68%, 49%, 40%, and 31% respectively, while the 1, 2, 3, 5-year survival rates in the S + R group were 75%, 45%, 30%, and 20% respectively, for which the differences in the two groups were statistically significance (p < 0.001), given that the 1-year OS appeared superior in the R + S group whereas the 2,3,5-year OSs were better in the S group, as demonstrated in Fig. 1b.

The univariate and multivariate analysis of the entire cohort showed that factors including age, gender, diagnosis year, primary site, ICD-0-3 classification, summary stage, AJCC 7th stage, T, N, M, surgery primary tumor site (surgery T), surgery regional lymph node (surgery N), additional radiotherapy and chemotherapy were related to OS, as shown in Table S2. Factors such as patients in the R + S group (HR 0.89, 95%CI: 0.86–0.92), additional chemotherapy (HR 0.75, 95%CI: 0.72–0.77), diagnosis year between 1999–2006 (HR 0.88, 95%CI: 0.80–0.98) and 2007–2016 (HR 0.80, 95%CI: 0.72–0.89), pancreatic duct tumor (HR 0.82, 95%CI: 0.73–0.92), neuroendocrine neoplasms (HR 0.16, 95%CI: 0.15–0.18), mesenchymal tumor (HR 0.42, 95%CI: 0.32–0.55), mucinous adenocarcinoma (HR 0.63, 95%CI: 0.59–0.68), carcinoma (HR 0.49, 95%CI: 0.43–0.55), and other histologic type (HR 0.60, 95%CI: 0.56–0.64), and
number of dissected lymph node with 1–3 (HR 0.89, 95% CI: 0.83–0.97), and more than 4 (HR 0.78, 95% CI: 0.73–0.83) were associated with lower risk of mortality. On the other hand, factors as independent predictors of higher mortality were age at 20–44 (HR 5.46, 95% CI: 2.82–10.56), 45–64 (HR 7.46, 95% CI: 3.86–14.39), 65–84 (HR 9.28, 95% CI: 4.81–17.9), ≥ 85 (HR 11.86, 95% CI: 6.11–23.03), tumor overlapping lesion of pancreas (HR 1.19, 95% CI: 1.02–1.18), adenosquamous carcinoma and squamous (HR 1.12, 95% CI: 0.99–1.27), regional invasion (HR 2.15, 95% CI: 2.03–2.27), distant involvement (HR 3.66, 95% CI: 3.42–3.91), T2 (HR 1.51, 95% CI: 1.33–1.73), T3 (HR 1.69, 95% CI: 1.47–1.96), T4 (HR 1.60, 95% CI: 1.23–2.09), N1 (HR 1.49, 95% CI: 1.41–1.57) and total pancreatectomy (HR 1.14, 95% CI: 1.08–1.21).

3.3 Stratification analysis by subgroup population

Our analysis showed that the median survival and OS of patients in the S group were better than the S + R group (p < 0.001), and additional radiotherapy was a reverse risk factor for prognosis. To investigate the specific patient population that benefited from the radiotherapy, stratified analyses of prognosis in different subgroups were performed. The median survival and OS between the two groups were significantly different in the subcategories, as shown in Table S3. First, the median survivals based on histologic types classified by adenocarcinoma/carcinoma, infiltrating duct carcinoma, adenosquamous carcinoma, and squamous in the S group and S + R group were 15 (95% CI: 15–16) vs 21 (95% CI: 20–21) months (p < 0.0001), 17 (95% CI: 16–18) vs 21 (95% CI: 21–22) months (p < 0.0001), 10 (95% CI: 9–13) VS 18 (95% CI: 14–26) months (p < 0.0001), respectively, as demonstrated in Fig. 2a-2c. Second, patients with the pancreatic head (21 months, 95% CI 21–22) and duct tumor (28 months, 95% CI 25–40) had better survival prognosis in the S + R group, compared with 19 (95% CI 18–19) months (p = 0.0003) and 18 (95% CI: 15–24) months (p < 0.0001) in the S group, respectively, as shown in Fig. 2d, Table S3. However, patients with pancreatic body/tail tumor (56 months, 95% CI 51–61) were not survival benefit from adjuvant radiotherapy (22 months, 95% CI 21–24) (p < 0.0001), as seen in Fig. 2e. Last, specific tumor stages demonstrated variable benefits to radiotherapy. Patients with regional invasion were the main beneficiaries, as shown in Fig. 2c. Also, patients staged by AJCC 7th II and III had median survivals of 26 (95% CI: 24–27) and 21 (95% CI: 19–25) months in the S + R group respectively, which were significantly better when compared with 22 (95% CI: 21–22) (p < 0.0001) and (95% CI: 13–16) 14 months (p < 0.0001) in the S group (Fig. 2g,2h). The median survival of T3, T4, N1 in the S + R and S group were 25 (95% CI: 24–26) vs 20 (95% CI: 19–21) months (p < 0.0001), 21 (95% CI: 19–24) vs 13 (95% CI: 12–16) months (p < 0.0001), and 24 (95% CI: 22–25) vs 18 (95% CI: 18–19) months (p < 0.0001), respectively, as shown in Fig. 2i, 2j, and 2k. Furthermore, the modality of resection as well as chemotherapy had induced variability in patients benefited from radiotherapy. In this instance, patients who underwent a total pancreatectomy and received radiotherapy had a better survival (20 months, 95% CI: 19–21) than those without (19 months, 95% CI: 18–21) (p = 0.016), as shown in Fig. 2f, while the addition of chemotherapy conferred to significantly improved survival at 22 (95% CI: 21–23) vs 21 (95% CI: 20–22) months (p = 0.002), as demonstrated in Fig. 2l. On the other hand, there was no difference in the survival in the subset analyses of factors including the number of removed lymph nodes, histologic grade, age, and race, as shown in Table S3.
3.4 Interaction analyses for Subgroups and sub-stratification

The stratified analysis showed that patients with the pancreatic body and tail tumors did not benefit from additional radiotherapy, but the subpopulations with specific histologic behavior, stage, and surgical approaches benefited from additional radiotherapy. Therefore, we next investigated whether the additional radiotherapy to survival benefits in the S + R group would be observed at different primary site combined with other features, as shown in TableS4. In this instance, patients with pancreatic head cancer, regional pancreatectomy (22 months, 95%CI: 21–22 vs 19 months, 95%CI: 18–20, p < 0.0001), and the number of lymph node excision of more than 4 (23 months, 95%CI: 22–24 vs 20 months, 95%CI: 19–21, p < 0.0001) derived survival benefits to additional radiotherapy, as shown in Fig. 3a and 3b. On the other hand, patients with pancreatic body/tail histologic classified by adenocarcinoma/carcinoma (21 months, 95%CI: 19–23 vs 15 months, 95%CI: 14–17, P < 0.0001) and infiltrating duct carcinoma (22 months, 95%CI: 20–26 vs 17 months, 95%CI: 16–10, P < 0.0001), T4 stage (24 months, 95%CI: 17–34 vs 12 months, 95% CI: 9–13, P = 0.027), III stage (24 months, 95%CI: 18–34 vs 12 months, 95% CI: 9–18, P = 0.018) were identified as highly selection groups that benefited from additional radiotherapy, as shown in Fig. 3c-3f. Unexpectedly, patients with staged N1 disease (pancreatic body/tail) had no survival benefit from additional radiotherapy. Moreover, more patients with pancreatic head cancer appeared to have a significantly better survival outcome.

3.5 Interaction analyses of the primary site combined histologic subgroup

To further investigate for factors in patients with pancreatic body and tail malignancies that benefited from additional radiotherapy, the three-factor combination among histologic type, primary site, and other clinicopathologic features were additionally refined. In this sub-stratified evaluation, other tumor sites and histologic behavior were excluded due to small sample size, as well as definitive survival benefits from surgery alone and reverse risk for survival, as shown in TableS2 and TableS4. Except for patients with stage T1 disease and infiltrating duct carcinomas, almost all patients with pancreatic head cancer had an improved survival following additional radiotherapy, as demonstrated in TableS5. Unexpectedly, patients with AJCC 7th stage I disease with adenocarcinoma/carcinoma and infiltrating duct carcinoma in both pancreatic heads (21 months, 95%CI: 20–22 vs 15 months, 95%CI: 15–16, p < 0.0001) and body/tail (21 months, 95%CI: 19–23 vs 15 months, 95%CI: 14–17, p < 0.0001) had improved survival prognosis with additional radiotherapy, as shown Fig. 4a-4d. Similar survival benefit from additional radiotherapy was also observed in patients with stage T2 adenocarcinoma of the pancreatic head (29 months, 95%CI: 22–38 vs 20 months, 95%CI: 17–25, p < 0.05), as shown in Fig. 4e. Almost all patients with pancreatic body/tail adenosquamous carcinoma/squamous had no survival benefit from additional radiotherapy, as shown in TableS5. However, a higher number of patients with pancreatic body/tail cancer of adenocarcinoma/carcinoma in staged T3, N1, additional chemotherapy, and any number of
lymphadenectomies showed better survival when received additional radiotherapy, as seen in TableS5, Fig. 4f-4i. From here, a further sub-stratified analysis was not performed due to the small sample size.

3.6 The sequence of surgery and radiotherapy and survival, radio source

Following the identification of a specific patient population that benefited from the additional radiotherapy in addition to surgery, the next concern involving the sequence between surgery and radiotherapy was addressed, as demonstrated in TableS6. A total of 7664 and 1099 patients received adjuvant and neoadjuvant radiotherapy respectively. The median survival was 21 months (95%CI: 20–22) vs 25 months (95%CI: 23–27), while the 1, 3, and 5-year OSs were 74%, 29%, and 20% vs 81%, 35%, and 20% in the adjuvant and neoadjuvant populations respectively, for which the differences were statistically significant (p = 0.001), as shown in Fig. 5a. There were 76 patients that received radiotherapy both before and after surgery, with the median survival of 26 months (95%CI: 20–32) and the 1, 3, and 5-year OS of 85%, 32%, and 19% respectively, which were significantly better than those having either radiotherapy before or after surgery only (p = 0.002), as shown in Fig. 5b. Last, a small proportion of patients had intraoperative radiotherapy with or without further adjuvant radiotherapy, for which the survival difference between these two subgroups was not statistically significant (p = 0.588), as shown in Fig. 5c.

4 Discussion

Adjuvant chemotherapy or radiotherapy in combination with surgery has been the standard of treatment for pancreatic cancer for decades.\(^3\) External beam radiotherapy is one of the most important treatment as it contributes to better survival.\(^3\)–\(^16\) In this study, we determined the potential patient population who might be benefited from having additional radiotherapy. Our primary survival analysis indicated that the benefit from additional radiotherapy was critically time-dependent and if extending the time window of more than 24 months, the treatment benefit from extension could be reverse. However, the multivariate analysis showed that additional radiotherapy was an independent prognostic factor for OS (HR 0.89, 95%CI 0.86–0.92, P < 0.0001). Moreover, earlier studies have demonstrated that patients treated with radiotherapy had significantly better survival than those without \(^7,8,11\)–\(^21\). The conflicting results we observed might be attributed to the differences in the baseline characteristics of patients as a result of retrospective selection bias. Patients who had received additional radiotherapy were of a poor prognostic group with several high-risk factors, including advanced stage, anatomic site, and unfavorable histologic classification.\(^22\)–\(^29\) Despite these, our study showed that patients with the above unfavorable features could still benefit from additional radiotherapy.

Pancreatic head has been shown to be the most common anatomical site for cancer followed by the pancreatic body and tail, with the latter displaying poorer survival than pancreatic head lesions.\(^29\) Adenosquamous carcinoma of the pancreas has a higher prevalence in the pancreatic tail and
associated with poor survival.\textsuperscript{22} In our study, the sample size of adenosquamous/squamous carcinoma was small and the patients with pancreatic body/tail cancer did not appear to benefit from additional radiotherapy. Patients with pancreatic neuroendocrine cancer have a better life expectancy,\textsuperscript{24,25} and resection of the primary tumor is associated with longer survival in stages I–III as well as stage IV tumors.\textsuperscript{26} Therefore, representing as the third most common tumor type, patients with pancreatic neuroendocrine cancer in our study had extremely good survival prognosis after surgical resection. A similarly favorable survival outcome was observed in patients with mesenchymal tumors or mucinous adenocarcinoma. In short, patients with pancreatic head cancer or cancer of certain histologic subtypes such as non-adenocarcinoma/carcinoma, non-infiltrating duct carcinoma, or non-adenosquamous carcinoma might benefit from additional radiotherapy.

To date, pancreatic adenocarcinoma/carcinoma and infiltrating duct carcinoma are still the most difficult to treat. Also, small pancreatic cancers have been associated with poorer survival prognosis and an extremely high rate of nodal involvement, for which they should not be regarded as early-stage cancers.\textsuperscript{30} Similar findings were observed in our study, in which additional radiotherapy significantly contributed to improving survival in patients with stage I/II adenocarcinoma/carcinoma and infiltrating duct carcinoma located in either pancreatic head or body/tail. However, based on the AJCC 7th classification, stage I/II disease indicates a T1/T2 tumor that is localized within the pancreas. Our data showed that additional radiotherapy for patients with T2 tumors in the pancreatic head or T1 tumors in the pancreatic head or body/tail did not confer to survival benefit, though this observation might be attributed to the small sample size. In the current National Comprehensive Cancer Network (NCCN) guideline (https://www.nccn.org), an early-stage pancreatic carcinoma refers to a resectable tumor. Neoadjuvant therapy can be considered in a clinical trial or with chemotherapy alone, or induction chemotherapy followed by chemotherapy, especially in the presence of high-risk factors. In addition, chemoradiation should not be given to patients after surgery except in clinical trials.\textsuperscript{31} Importantly, most clinical trials have been focusing on comparing chemotherapy with or without chemoradiotherapy, and few trials have examined the effectiveness of radiotherapy alone. Our study demonstrated that patients with stage I/II or T2 disease had an improved survival from additional radiotherapy, suggesting that those subpopulation patients especially with high-risk features and did not receive neoadjuvant treatment could be considered for adjuvant radiotherapy. The AJCC 8th stage system was prior to current stage for involved in clear T stage,\textsuperscript{32} and future prospective clinical study should be designed to take into account patients with diseases of early stages.

Our study demonstrated that locally advanced (T3/4, N\textsuperscript{+}) pancreatic adenocarcinoma/carcinoma or infiltrating duct carcinoma had improved survival prognosis following additional radiotherapy, regardless of tumor location. Several studies have found adjuvant treatment after surgery contributed to improved survival in advanced pancreatic cancer.\textsuperscript{3,3–7,11,13,33,34} Other clinical trials have confirmed neoadjuvant treatment was prior to adjuvant treatment,\textsuperscript{3,5,8,14,21,35} in fact, most patients preferentially received resection, more than 80% of patients were in the station in current study (Table S6). Surprisingly, our study showed that patients who benefited from radiotherapy were those who received chemotherapy, and
this was in keeping with the results of previous studies which demonstrated that chemoradiotherapy or chemotherapy sequencing with radiotherapy was beneficial for survival improvement. An increased number of lymph nodes dissection has been shown to be a poor prognostic factor for OS,\textsuperscript{36} with higher lymph node retrieval associated with a higher proportion of positive invasion. Our study showed that patients with more than four lymph node dissection had a favorable survival when treated with additional radiotherapy. Therefore, radiotherapy can improve cancer survival compared with cancer-directed surgery without radiation in patients with adenocarcinoma of the pancreas.\textsuperscript{19} Patients with advanced disease regardless of tumor location should be considered for radiotherapy and chemotherapy.

5 Conclusion

Patients with pancreatic cancer of specific histological types (adenocarcinoma/carcinoma, infiltrating duct carcinoma, adenosquamous carcinoma, and squamous), anatomical location, and advanced stage have poor survival and therefore additional radiotherapy may contribute to an improved survival prognosis. A specific subgroup of patients with an early stage (I/II, T2) pancreatic cancer should be considered for additional radiotherapy. Our findings highlight the positive role of radiotherapy in highly selected patients with pancreatic malignancy, suggesting the need for future prospective randomized control study to confirm these findings before recommending such treatment to patients.

Declarations

Ethics approval and consent to participate

The study had been ethics approved for original institution.

Consent for publication

All authors have read and agreed to the published version of the manuscript.

Availability of data and materials

The original data related to the paper can be provided by the corresponding author

Conflict of Interest:

The authors declare no conflicts of interest

Funding:
Not applicable.

Authors’ Contributions:

Yunxiu Luo, data analysis and writing; Shengjun Xiao, review and revising.

Acknowledgments:

We thank NIH for its dataset during the preparation of this manuscript.

References

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians. 2018;68(6):394–424. doi:10.3322/caac.21492

2. Ferlay J, Partensky C, Bray F. More deaths from pancreatic cancer than breast cancer in the EU by 2017. Acta Oncologica (Stockholm, Sweden). 2016;55(9–10):1158–1160. doi:10.1080/0284186X.2016.1197419

3. Neuzillet C, Gaujoux S, Williet N, Bachet J-B, Bauguion L, Colson Durand L, Conroy T, Dahan L, Gilabert M, Huguet F, et al. Pancreatic cancer: French clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, AFC). Digestive and Liver Disease: Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver. 2018;50(12):1257–1271. doi:10.1016/j.dld.2018.08.008

4. Van Laethem J-L, Hammel P, Mornex F, Azria D, Van Tienhoven G, Vergauwe P, Peeters M, Polus M, Praet M, Maurer M, et al. Adjuvant gemcitabine alone versus gemcitabine-based chemoradiotherapy after curative resection for pancreatic cancer: a randomized EORTC-40013-22012/FFCD-9203/GERCOR phase II study. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2010;28(29):4450–4456. doi:10.1200/JCO.2010.30.3446

5. Moureau-Zabotto L, Phélip J-M, Afchain P, Mineur L, André T, Vendrely V, Lledo G, Dupuis O, Huguet F, Touboul E, et al. Concomitant administration of weekly oxaliplatin, fluorouracil continuous infusion, and radiotherapy after 2 months of gemcitabine and oxaliplatin induction in patients with locally advanced pancreatic cancer: a Groupe Coordinateur Multidisciplinaire en Oncologie phase II study. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2008;26(7):1080–1085. doi:10.1200/JCO.2007.12.8223

6. Sugawara A, Kunieda E. Effect of adjuvant radiotherapy on survival in resected pancreatic cancer: a propensity score surveillance, epidemiology, and end results database analysis. Journal of Surgical Oncology. 2014;110(8):960–966. doi:10.1002/jso.23752

7. Hammel P, Huguet F, van Laethem J-L, Goldstein D, Glimelius B, Artru P, Borbath I, Bouché O, Shannon J, André T, et al. Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally
Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib: The LAP07 Randomized Clinical Trial. JAMA. 2016;315(17):1844–1853. doi:10.1001/jama.2016.4324

8. Dobiasch S, Goerig NL, Fietkau R, Combs SE. Essential role of radiation therapy for the treatment of pancreatic cancer: Novel study concepts and established treatment recommendations. Strahlentherapie Und Onkologie: Organ Der Deutschen Rontgengesellschaft ... [et Al]. 2018;194(3):185–195. doi:10.1007/s00066-017-1227-5

9. Krishnan S, Chadha AS, Suh Y, Chen H-C, Rao A, Das P, Minsky BD, Mahmood U, Delclos ME, Sawakuchi GO, et al. Focal Radiation Therapy Dose Escalation Improves Overall Survival in Locally Advanced Pancreatic Cancer Patients Receiving Induction Chemotherapy and Consolidative Chemoradiation. International Journal of Radiation Oncology, Biology, Physics. 2016;94(4):755–765. doi:10.1016/j.ijrobp.2015.12.003

10. Louvet C, André T, Lledo G, Hammel P, Bleiberg H, Bouleuc C, Gamelin E, Flesch M, Cvikovic E, de Gramont A. Gemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma: final results of a GERCOR multicenter phase II study. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2002;20(6):1512–1518. doi:10.1200/JCO.2002.20.6.1512

11. Takano N, Yamada S, Hirakawa A, Yokoyama Y, Kawashima H, Maeda O, Okada T, Ohno E, Yamaguchi J, Ishikawa T, et al. Phase II study of chemoradiotherapy combined with gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic ductal adenocarcinoma (NUPAT 05 Trial): study protocol for a single arm phase II study. Nagoya Journal of Medical Science. 2019;81(2):233–239. doi:10.18999/nagjms.81.2.233

12. Thomas PR. Radiotherapy for carcinoma of the pancreas. Seminars in Oncology. 1996;23(2):213–219.

13. Lim YJ, Kim K, Chie EK, Kim B, Ha SW. Role of Adjuvant Radiotherapy in Left-Sided Pancreatic Cancer-Population-Based Analysis with Propensity Score Matching. Journal of Gastrointestinal Surgery: Official Journal of the Society for Surgery of the Alimentary Tract. 2015;19(12):2183–2191. doi:10.1007/s11605-015-2941-x

14. Landau E, Kalnicki S. The Evolving Role of Radiation in Pancreatic Cancer. The Surgical Clinics of North America. 2018;98(1):113–125. doi:10.1016/j.suc.2017.09.008

15. Sajjad M, Batra S, Hoffe S, Kim R, Springett G, Mahipal A. Use of Radiation Therapy in Locally Advanced Pancreatic Cancer Improves Survival: A SEER Database Analysis. American Journal of Clinical Oncology. 2018;41(3):236–241. doi:10.1097/COC.0000000000000261

16. Johung K, Saif MW, Chang BW. Treatment of locally advanced pancreatic cancer: the role of radiation therapy. International Journal of Radiation Oncology, Biology, Physics. 2012;82(2):508–518. doi:10.1016/j.ijrobp.2011.08.008

17. Badiyan SN, Molitoris JK, Chuong MD, Regine WF, Kaiser A. The Role of Radiation Therapy for Pancreatic Cancer in the Adjuvant and Neoadjuvant Settings. Surgical Oncology Clinics of North America. 2017;26(3):431–453. doi:10.1016/j.soc.2017.01.012
18. Huguet F, Goodman KA, Azria D, Racadot S, Abrams RA. Radiotherapy technical considerations in the management of locally advanced pancreatic cancer: American-French consensus recommendations. International Journal of Radiation Oncology, Biology, Physics. 2012;83(5):1355–1364. doi:10.1016/j.ijrobp.2011.11.050

19. Hazard L, Tward JD, Szabo A, Shrieve DC. Radiation therapy is associated with improved survival in patients with pancreatic adenocarcinoma: results of a study from the Surveillance, Epidemiology, and End Results (SEER) registry data. Cancer. 2007;110(10):2191–2201. doi:10.1002/cncr.23047

20. Hall WA, Goodman KA. Radiation therapy for pancreatic adenocarcinoma, a treatment option that must be considered in the management of a devastating malignancy. Radiation Oncology (London, England). 2019;14(1):114. doi:10.1186/s13014-019-1277-1

21. Stessin AM, Meyer JE, Sherr DL. Neoadjuvant radiation is associated with improved survival in patients with resectable pancreatic cancer: an analysis of data from the surveillance, epidemiology, and end results (SEER) registry. International Journal of Radiation Oncology, Biology, Physics. 2008;72(4):1128–1133. doi:10.1016/j.ijrobp.2008.02.065

22. Boyd CA, Benarroch-Gampel J, Sheffield KM, Cooksley CD, Riall TS. 415 patients with adenosquamous carcinoma of the pancreas: a population-based analysis of prognosis and survival. The Journal of Surgical Research. 2012;174(1):12–19. doi:10.1016/j.jss.2011.06.015

23. Song Y, Chen Z, Chen L, He C, Huang X, Duan F, Wang J, Lao X, Li S. A Refined Staging Model for Resectable Pancreatic Ductal Adenocarcinoma Incorporating Examined Lymph Nodes, Location of Tumor and Positive Lymph Nodes Ratio. Journal of Cancer. 2018;9(19):3507–3514. doi:10.7150/jca.26187

24. Fesinmeyer MD, Austin MA, Li CI, De Roos AJ, Bowen DJ. Differences in survival by histologic type of pancreatic cancer. Cancer Epidemiology, Biomarkers & Prevention: A Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology. 2005;14(7):1766–1773. doi:10.1158/1055-9965.EPI-05-0120

25. Brooks JC, Shavelle RM, Vavra-Musser KN. Life expectancy in pancreatic neuroendocrine cancer. Clinics and Research in Hepatology and Gastroenterology. 2019;43(1):88–97. doi:10.1016/j.clinre.2018.08.005

26. Keutgen XM, Nilubol N, Kebebew E. Malignant-functioning neuroendocrine tumors of the pancreas: A survival analysis. Surgery. 2016;159(5):1382–1389. doi:10.1016/j.surg.2015.11.010

27. Murakami Y, Uemura K, Sudo T, Hayashidani Y, Hashimoto Y, Nakashima A, Yuasa Y, Kondo N, Ohge H, Sueda T. Number of metastatic lymph nodes, but not lymph node ratio, is an independent prognostic factor after resection of pancreatic carcinoma. Journal of the American College of Surgeons. 2010;211(2):196–204. doi:10.1016/j.jamcollsurg.2010.03.037

28. Makarova-Rusher OV, Ulahannan S, Greten TF, Duffy A. Pancreatic Squamous Cell Carcinoma: A Population-Based Study of Epidemiology, Clinicopathologic Characteristics and Outcomes. Pancreas. 2016;45(10):1432–1437. doi:10.1097/MPA.0000000000000658
29. Artinyan A, Soriano PA, Prendergast C, Low T, Ellenhorn JDI, Kim J. The anatomic location of pancreatic cancer is a prognostic factor for survival. HPB: the official journal of the International Hepato Pancreato Biliary Association. 2008;10(5):371–376. doi:10.1080/13651820802291233

30. Franko J, Hugec V, Lopes TL, Goldman CD. Survival among pancreaticoduodenectomy patients treated for pancreatic head cancer <1 or 2 cm. Annals of Surgical Oncology. 2013;20(2):357–361. doi:10.1245/s10434-012-2621-y

31. Ducreux M, Cuhna ASa, Caramella C, Hollebecque A, Burtin P, Goërê D, Seufferlein T, Haustermans K, Van Laethem JL, Conroy T, et al. Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 2015;26(suppl 5):v56–v68. doi:10.1093/annonc/mdv295

32. Kamarajah SK, Burns WR, Frankel TL, Cho CS, Nathan H. Validation of the American Joint Commission on Cancer (AJCC) 8th Edition Staging System for Patients with Pancreatic Adenocarcinoma: A Surveillance, Epidemiology and End Results (SEER) Analysis. Annals of Surgical Oncology. 2017;24(7):2023–2030. doi:10.1245/s10434-017-5810-x

33. Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Gastrointestinal Tumor Study Group. Cancer. 1987;59(12):2006–2010. doi:10.1002/1097-0142(19870615)59:12<2006::aid-cncr2820591206>3.0.co;2-b

34. Huguet F, André T, Hammel P, Artru P, Balosso J, Selle F, Deniaud-Alexandre E, Ruszniewski P, Touboul E, Labianca R, et al. Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2007;25(3):326–331. doi:10.1200/JCO.2006.07.5663

35. Vera R, Dotor E, Feliu J, González E, Laquente B, Macarulla T, Martínez E, Maurel J, Salgado M, Manzano JL. SEOM Clinical Guideline for the treatment of pancreatic cancer (2016). Clinical & Translational Oncology: Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico. 2016;18(12):1172–1178. doi:10.1007/s12094-016-1586-x

36. He C, Zhang Y, Cai Z, Lin X, Li S. Overall survival and cancer-specific survival in patients with surgically resected pancreatic head adenocarcinoma: A competing risk nomogram analysis. Journal of Cancer. 2018;9(17):3156–3167. doi:10.7150/jca.25494

**Figures**
Figure 1

a, cumulative overall survival (OS) curves of all patients with pancreatic cancer; b, OS curves of patients undergoing surgery alone (S) or surgery combined with radiotherapy (S+R). The log-rank test showed that the OS was significantly different between the two groups (P<0.0001). S: surgery, S+R: surgery plus radiotherapy.

Figure 2

(a) Adenocarcina/carcinoma
- S Group
- S+R Group

(b) Infiltrating duct carcinoma
- S Group
- S+R Group

(c) Adenosquamous carcinoma
- S Group
- S+R Group

(d) Pancreatic head
- S Group
- S+R Group

(e) Pancreatic body/tail
- S Group
- S+R Group

(f) Total pancreatectomy
- S Group
- S+R Group

(g) AJCC 7th stage II
- S Group
- S+R Group

(h) AJCC 7th stage III
- S Group
- S+R Group

(i) AJCC 7th stage IV
- S Group
- S+R Group

(j) AJCC 7th N1
- S Group
- S+R Group

(k) Chemotherapy
- S Group
- S+R Group

(l) S+R Group
Cumulative overall survival (OS) curves of patients with stratification analysis in surgery alone group and surgery plus radiotherapy group with a log-rank test. a, adenocarcinoma/carcinoma (p<0.0001); b, infiltrating duct carcinoma (p<0.0001); c, adenosquamous carcinoma / squamous (p=0.00085); d, primary site located in pancreatic head (p=0.00029); e, primary site located in pancreatic body/tail (p<0.0001); f, primary tumor with total pancreatectomy (p=0.016); g, AJCC 7th stage II (p<0.0001); h, AJCC 7th stage III (p= p<0.0001); i, AJCC 7th stage T3 (p<0.0001); j, AJCC 7th stage T4 (p<0.0001); k, AJCC 7th N1 (p<0.0001); l, patients received chemotherapy (p=0.002).

Figure 3
Cumulative overall survival (OS) curves of patients with pancreatic head and body/tail cancer with sub-stratification analysis in surgery alone group and surgery plus radiotherapy group with a log-rank test, which demonstrated a subpopulation of patients that benefited from additional radiotherapy. a, patients with pancreatic head cancer received partial pancreatectomy (p<0.0001); b, patients with pancreatic head cancer dissected more than 4 lymph nodes (p<0.0001); c, patients with pancreatic body/tail adenocarcinoma/carcinoma (p<0.0001); d, patients with pancreatic body/tail infiltrating duct carcinoma (p<0.0001); e, c, patients with pancreatic body/tail cancer staged AJCC 7th T4 (p=0.026); f, c, patients with pancreatic body/tail adenocarcinoma/carcinoma AJCC 7th staged III (p=0.027).
Figure 4

Cumulative overall survival (OS) curves of patients with pancreatic head and body/tail adenocarcinoma/carcinoma or infiltrating duct carcinoma, the sub-stratification analysis in surgery alone group and surgery plus radiotherapy group with a log-rank test, which demonstrated a subpopulation of patients that benefited from additional radiotherapy. a, patients with pancreatic head adenocarcinoma/carcinoma AJCC 7th staged I (p<0.0001); b, patients with pancreatic head infiltrating duct carcinoma AJCC 7th staged I (p<0.0001); c, patients with pancreatic head adenocarcinoma/carcinoma AJCC 7th staged T2 (p=0.049); d, patients with pancreatic body/tail adenocarcinoma/carcinoma AJCC 7th staged I (p<0.0001); e, patients with pancreatic body/tail infiltrating duct carcinoma AJCC 7th staged I (p=0.00068); f, patients with pancreatic body/tail adenocarcinoma/carcinoma AJCC 7th staged T3 (p<0.0001); g, patients with pancreatic body/tail adenocarcinoma/carcinoma AJCC 7th staged N1 (p<0.0001); h, patients with pancreatic body/tail infiltrating duct carcinoma AJCC 7th staged I (p<0.0001); i, patients with pancreatic body/tail adenocarcinoma/carcinoma and received chemotherapy (p=0.00092).
Figure 5

Cumulative overall survival (OS) curves of patients with pancreatic cancer, the sub-stratification analysis of sequence between radiotherapy and surgery with a log-rank test. a, adjuvant and neoadjuvant radiotherapy (p=0.001); b, adjuvant, neoadjuvant, and both; c, intraoperative radiotherapy plus radiotherapy and intraoperative therapy alone (p=0.588).

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- SupplementaryTable.xlsx
- figs1.tif